|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization expense | |||||
| Non-cash interest expense (debt discount and deferred costs) | |||||
| Net amortization of premiums and accretion of discounts on marketable securities | |||||
| Gain on change in fair value of derivatives | |||||
| Exchange-related gain, net | |||||
| Stock-based compensation expense | |||||
| Provision for inventory obsolescence and losses | |||||
| Loss on disposal of assets | |||||
| Other | |||||
| Allowance for credit losses | |||||
| Changes in assets and liabilities: | |||||
| Accounts receivable | |||||
| Prepaid expenses and other current assets | |||||
| Inventory | |||||
| Deposits and other assets | |||||
| Accounts payable | |||||
| Accrued expenses and other liabilities | |||||
| Accrued interest | |||||
| Operating lease liabilities | |||||
| Payments on lease liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities | |||||
| Capital expenditures | |||||
| Purchase of marketable securities | |||||
| Proceeds from sale and maturity of marketable securities | |||||
| Net cash (used in) provided by investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from issuance of common stock, net | |||||
| Proceeds from exercise of stock options, RSUs and ESPP issuances, net | |||||
| Proceeds from issuance of term loan, net | |||||
| Taxes paid related to net share settlement of equity awards | |||||
| Proceeds from issuance of the RD Shares and the PP Warrants | |||||
| Payment of debt issuance costs | |||||
| Proceeds from issuance of Purchase Warrant, net | |||||
| Payment of debt modification costs | |||||
| Net cash provided by financing activities | |||||
| Net decrease in cash and cash equivalents | |||||
| Cash and cash equivalents and restricted cash, at beginning of period | |||||
| Cash and cash equivalents and restricted cash, at ending of period | |||||
| Supplemental disclosure of cash flow information | |||||
| Cash paid during the period for interest | |||||
| Lease liabilities arising from obtaining right-of-use assets | |||||
| Supplemental disclosure of non-cash transactions | |||||
| Issuance of common stock converted from preferred shares | |||||
| Property and equipment purchases included in accounts payable and accrued expenses | |||||
| Issuance of warrants in exchange for PHC Notes | |||||
| Issuance of warrants for Loan and Security Agreement | |||||
| Issuance of common stock converted from 2025 Notes | |||||
| Change in exercise price of warrants due to Amended Loan and Security Agreement | |||||
| Acquisition of sensor insertion network assets in exchange for accounts receivable | |||||
| Liabilities for contingent consideration | |||||
Loading...